Skip to main content

Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis



Systemic sclerosis (SSc) is a multi-organ disease with impaired health-related quality of life (HRQoL). The EULAR SSc Impact of Disease (ScleroID) is a newly introduced SSc-specific patient-reported outcome to evaluate HRQoL in SSc.


To investigate the correlation between the ScleroID and the involvement of organ systems as well as disease activity/damage in a SSc cohort from a large tertiary care centre.

Patients and methods

The ScleroID and clinical characteristics including internal organ involvement and hand function were investigated in 160 consecutive patients with SSc (median age 46 (43;56) years; diffuse cutaneous SSc 55%).


A strong correlation was found between the ScleroID and articular disease activity scores (DAS28-CRP, DAS28-ESR, CDAI, SDAI), a hand function performance test, the Hand Anatomy Index and muscle strength tests. Additionally, a strong significant correlation was discovered using instruments representing hand function and musculoskeletal disability including the Cochin Hand Function Scale, the Quick Questionnaire of the Disability of the Hands, Arms and the Shoulders and the Health Assessment Questionnaire Disability Index. A significant negative correlation was found between the ScleroID score and the 6-min walking test (6MWT) (rho − 0.444, p < 0.001). Clinically mild lung/heart disease did not show increased ScleroID values. The Mouth Handicap in the Scleroderma Scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 also showed significant positive correlations to the ScleroID score (rho: 0.626, p < 0.001; rho: 0.646, p < 0.001, respectively). Patients experiencing oesophageal difficulties bore a significantly higher score compared to individuals with a normal functioning oesophagus (3.2/1.5;4.5/ vs. 2.2/1.0;3.2/, p = 0.011). Moreover, the ScleroID showed a significant positive correlation to the revised EUSTAR disease activity index and modified activity index.


In a large single-centre cohort, the previously described ScleroID-related findings were confirmed. Furthermore, several organ involvement-related functional and performance tests showed a good correlation to the ScleroID including the 6MWT and gastrointestinal-related complaints. Many aspects of musculoskeletal damage, overall disease activity, pain and fatigue were also well represented in the ScleroID, which efficiently reflects the impact of organ involvement, disease activity and functional damage.


Systemic sclerosis (SSc) is a multiorgan systemic disease affecting both internal organs and the musculoskeletal system resulting in decreased health-related quality of life (HRQoL) [1,2,3] and survival [4, 5]. Measuring HRQoL is challenging as since many aspects of quality of life are affected in SSc. It is well known that the general health in SSc (measured with Short-Form Health-Survey 36 (SF36)) is substantially impaired when compared to healthy subjects [6] and a high level of disability is present in patients affected with SSc [7,8,9,10].

HRQoL can be assessed using general instruments (e.g. SF-36) [11, 12], disease group instruments representing musculoskeletal disability (e.g. Health Assessment Questionnaire Disability Index (HAQ-DI)) [7, 11, 13] and disease-specific tools (e.g. University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract (UCLA-GIT) [14, 15]. A novel disease-specific questionnaire, a patient-reported outcome measure (PROM), was recently introduced for SSc, later named the EULAR Systemic sclerosis Impact of Disease (ScleroID). It was validated in a multicentre cohort [16], and recently it has been translated and validated in the Hungarian language [17]. Developing PROMs are essential tools used in combatting a complex disease such as SSc, since it aids in both the decision-making among physicians and patient satisfaction [18].

HRQoL in SSc is strongly influenced by internal organ involvement (e.g. cardiac or pulmonary involvement) resulting in fatigue and exertional dyspnoea [1, 3, 8, 9]. Patients’ gastrointestinal symptoms, severity of Raynaud’s phenomenon and fatigue, are the biggest contributors to decreased QoL [9, 19, 20]. HRQoL may deteriorate due to patients’ musculoskeletal and vascular symptoms, such as contractures, digital ulcers or joint swelling/pain [9, 19, 21,22,23,24]. Articular involvement can appear early in the course of the disease and may result in contractures and disability [10, 25, 26]. Measuring decreased hand function can be assessed through the administering of different tests, including the Hand Anatomy Index (HAI) [27] and the Hand Mobility in SSc scale (HAMIS) [28]. Additionally, questionnaires can be disseminated (e.g. the Cochin Hand Function Scale-CHFS, the Quick Questionnaire of the Disability of the Hands and the Arms and Shoulders-qDASH) [29,30,31].

The recently developed ScleroID PROM aimed to capture the patients’ evaluation regarding their disease severity. Following the prioritization of different aspects of health dimensions in SSc patients, ten different items were selected to constitute the questionnaire. The simple questionnaire showed a good correlation with patients’ global assessment and sHAQ, it has good re-test reliability and sensitivity to change and was designed to measure the overall disease impact [16]. Herein, we aimed to further investigate its clinical correlations with musculoskeletal and internal organ involvements in a large SSc cohort.

Patients and methods

One hundred and sixty consecutive SSc patients fulfilling the 2013 ACR/EULAR criteria [32] were enrolled at the Department of Rheumatology and Immunology, Medical School, Pécs, Hungary, between June 2017 and July 2019. Patients with overlap syndromes were not excluded. The mean age of the patients was 55.7 ± 13.1 years. Median disease duration estimated from the first non-Raynaud symptom was 6.5 years (4;12). The disease duration in the subgroup of diffuse cutaneous SSc (dcSSc) was significantly lower when compared to the disease duration in the limited cutaneous SSc (lcSSc) subgroup (7.5/3;13/ vs. 12/7;17/, p = 0.001). Fifty-five per cent of patients (n = 88) had dcSSc. Fifty-five cases (34.4%) had a disease duration of less than 5 years, and among them 35 had dcSSc.

Internal organ involvement was defined based on the following criteria: Interstitial pulmonary involvement (ILD) was defined by two trained radiologists using high-resolution computed tomography (HRCT) [33]. Severe ILD was defined if the diffusing capacity of carbon monoxide (DLCO) was < 51% and forced vital capacity (FVC) < 80% with the presence of ILD on HRCT [34]. Pulmonary arterial hypertension (PAH) was recorded if > 25 mm Hg mean pulmonary arterial hypertension was detected by right heart catheterization (RHC) [35]. Patients having elevated right ventricular pressure on echocardiography were referred to RHC by the cardiologist based on a standard protocol. The overwhelming majority of the patients were examined by the same team of cardiologists [36]. Exertional dyspnea was a patient-reported item as reported during the interview. Heart disease was defined as the presence of either congestive heart disease, or pericardial disease or arrhythmia or relaxation disturbances [37]. The 6-min walk test (6MWT) was performed according to standard protocol [38] and the distance covered recorded. It was considered decreased in the case of less than 300 m [39]. Left ventricular mass index was also calculated based on echocardiographic results [36]. Oesophageal involvement was stated in the presence of stricture or dysmotility on barium swallow test [4]. GI involvement was categorized based on the UCLA GIT 2.0 score to mild, moderate and severe disease as described [14]. Scleroderma renal crisis was defined by a standard protocol [40]. HRCT findings were available in 134 cases, spirometry was performed in 159 cases, echocardiography was achieved in 146 cases and the 6 MWT was performed in 159 patients. Barium swallow test was performed in 153 patients, hand function tests were available in 159 cases and the set of questionnaires was duly reviewed and evaluated in all patients.

Disease activity was assessed using the European Scleroderma Study Group Activity Index (EScGAI), the Modified 9.5 point Activity Index developed by our team and also the revised EUSTAR Activity Index (EUSTAR-AI) [41,42,43]. Patients also completed the validated Hungarian version of the ScleroID tool [17].

To evaluate patients’ opinions, the validated Hungarian version of the self-assessment questionnaire was used including the HAQ-DI [13], CHFS [29], qDASH [30], skin thickness questionnaire [44], SF-36 [12], scleroderma HAQ (sHAQ) [45], Mouth Handicap in Scleroderma Scale (MHISS) [46] and UCLA-GIT 2.0 [14, 15]. The physician’s and patient’s global assessment, the joint pain and the degree of fatigue were also recorded through the use of a visual analogue scale (VAS).

To evaluate hand function in patients affected with SSc, validated articular activity scores including the Disease Activity Score 28 Erythrocyte Sedimentation Rate, the Disease Activity 28 Score C-Reactive Protein, the Simplified Disease Activity Index and the Clinical Disease Activity Index, (DAS28-ESR, DAS28-CRP, SDAI and CDAI, respectively) were calculated [24, 47]. Disability of the hand by performance tests was investigated with HAMIS [28] and HAI [27]. Muscle strength was described by calculating the Manual Muscle Test 8 (MMT8) [48]. Contractures were defined if the range of motion upon physical examination was less than 75% [22].


All patients submitted their informed written consent to the study, which was conducted in full accordance with the Declaration of Helsinki and was approved by the National Research Ethics Committee (30,636–3/2017/EKU).

Statistical analysis

SSc subgroups were compared using the Mann–Whitney U or the Kruskal–Wallis test in the case of continuous variables. Correlation analysis was performed using the Spearman correlation analysis. Since most of the continuous variables showed no normal distribution, data are given as median (lower quartile; upper quartile). The Random Forest (RF) analysis was used to detect potential predictors of the 6MWT, in which the significant contributors were placed into linear regression analyses to determine the independent contributors of 6MWT. Data were analysed using Statistica 6.0 (Tulsa, USA).


Clinical characteristics are detailed in Table 1.

Table 1 Clinical characteristics of 160 systemic sclerosis patients

The median overall ScleroID score was 2.3 (1.05;3.65). Regarding the SSc subsets, dcSSc cases had scored 2.3 (0.95;3.65) versus 2.4 (1.25;3.65) for lcSSc patients. There was no significant difference between the two subgroups (p = 0.856). The ScleroID score showed a good correlation with the Patient’s Global Assessment, yet not with the Physician’s Global Assessment in both lcSSc and dcSSc subsets. Furthermore, significant correlations were found with SF-36, HAQ-DI and SHAQ in both subgroups (Table 2).

Table 2 Correlation analysis of different self-assessment questionnaires and the ScleroID

The SF-36 Mental Component Score (SF-36 MCS) showed no significant difference between lcSSc and dcSSc (73.0/46.1;85.4/ vs. 59.1/37.6;81.0/; p = 0.062), while the SF-36 Physical Component Score (SF.36 PCS) was significantly higher in dcSSc (43.7/24.7;64,2/ vs. 51.9/28.7;76.2/; p = 0.038). When early and late disease in both subsets were compared, no significant difference was found regarding SF-36 MCS nor SF-36PCS. No difference was observed in consideration of HAQ-DI between lcSSc and dcSSc patients (data not shown). Patients with HAQ-DI ≤ 1 had significantly lower ScleroID scores when compared to the counterparts with HAQ-DI > 1 (1.4/0.7;2.4/ vs. 3.5/2.5;4.8/, p < 0.001).

Patients suffering from cardiac involvement did not have a significantly higher ScleroID score compared to those without (2.5/1.4;3.7/ vs. 2/0.9;3.5/, p = 0.173). No significant difference was found regarding the ScleroID score between patients with a preserved ejection fraction (> 50%) and a decreased ejection fraction (< 50%), between cases with and without diastolic dysfunction on echocardiography, and, with and without conduction disturbances on electrocardiogram (data not shown).

The ScleroID score showed a significant moderate negative correlation with the distance performed in the 6MWT (rho: − 0.440, p < 0.001), but not with calculated right ventricular pressure (cRVP) (rho: 0.051, p = 0.641) (Table 3). Patients with a decreased distance covered in the 6MWT had significantly lower ScleroID scores when compared to those with normal distances covered (1.95/1.0;3.3/ vs, 3.9/3.0;5.3/, p < 0.001). Patients with dyspnea class NYHA III/IV had significantly higher ScleroID scores when compared to patients with NYHA class I/ II (4.5/2.8;5.4/ vs. 2.2/1.0;3.5/, p < 0.001) (Fig. 1).

Table 3 Clinical correlations of ScleroID scoresa
Fig. 1
figure 1

Comparison of ScleroID values of cases with mild versus severe organ involvement. NYHA, New York Heart Association; HAQ-DI, Health Assessment Questionnaire disability Index; GI, gastrointestinal, ScleroID, EULAR Systemic sclerosis Impact of Disease; FVC, forced vital capacity

Based on binary logistic regression modelling, age, left ventricular mass index and the MMT8 score were the significant contributors to the distance performed on 6MWT (data not shown). When patients with knee contractures (n = 4) and patients with decreased MMT8 (n = 15) were excluded, the correlation between the ScleroID score and the 6MWT still remained significant (rho − 0.456 p < 0.001, rho − 0.381 p < 0.001, respectively).

Neither patients having ILD compared to cases without (2.5/1.2;4.0/ vs. 2.2/1.0;3.5/, p = 0.212), nor the patients having severe ILD compared to patients without (2.8/1.5;4.5/ vs. 2.3/1.0;3.6/ p = 0.547) showed significant differences in the ScleroID score. Patients with ≤ 50% FVC (n = 11) showed no significant difference regarding ScleroID score when compared to those with FVC > 50% (n = 148) (2.9 /1.2;3.8/ vs 2.3 /1.0;3.7/ p = 0.817).

Comparison of patients’ UCLA GIT 2.0 values showed a significant difference, in which patients with a mild case of the disease had the lower and the patients with severe disease had the highest ScleroID scores (1.8/0.9;3.0/ vs. 3.4/2.8;4.1/ vs. 6.0/5.3;6.6/, p < 0.001). Patients with oesophageal involvement had significantly higher scores when compared to those without (3.2/1.5;4.5/ vs. 2.2/1.0;3.2/, p = 0.011). Patients having malabsorption also had significantly higher ScleroID scores when compared to those without (3.5/2.3;3.9/ vs. 2.2/1.0;3.6/, p = 0.010) (Fig. 1).

Additionally, the ScleroID score showed strong correlations with the revised EULAR Activity Index (rho: 0.256, p = 0.001) and with the modified activity index (rho: 0.476, p < 0.001).

The ScleroID score showed a strong significant correlation with all articular disease activity scores (DAS28-CRP, DAS28-ESR, CDAI and SDAI) in the entire cohort and in both SSc subtypes. However, the number of swollen joints showed significant correlations with the ScleroID only upon examination of the entire cohort The ScleroID score also showed a significant positive correlation with hand disability indices including HAMIS in both hands and the number of contractures in the entire cohort (rho: 0.331, p = 0.000; rho: 0.185, p = 0.020, respectively). Regarding HAI, a significant negative correlation was found with the ScleroID in both hands (rho: − 0.283, p < 0.0001). Muscle strength evaluated by MMT-8 showed a significantly strong correlation with the ScleroID in all investigated groups (Fig. 2).

Fig. 2
figure 2

Clinical correlations of ScleroID and musculoskeletal performance tests, fatigue and DAS28-ESR. ScleroID, EULAR Systemic sclerosis Impact of Disease; VAS, visual analogue scale; DAS28, disease activity score erythrocyte sedimentation rate; HAMIS, hand mobility in systemic sclerosis scale

Patients with current or previous digital ulcers (DU) had significantly higher ScleroID scores when compared to those without DUs (3.2/1.6;4.0/ vs. 2.1/0.9;3.2/, p = 0.005); however, the ScleroID score did not correlate with the current number of DU. The calculated ScleroID score showed significant correlations with the number of shortened digits also (entire cohort rho: 0.18, p = 0.022; dcSSc: rho: 0.27 p = 0.010).

The analysis regarding self-assessment questionnaires showed strong correlations with all investigated questionnaires (MHISS, Skin thickness questionnaire, CHFS, qDASH and UCLA-GIT) in the entire cohort and both subsets. Lastly, both pain and fatigue visual analogue scales showed significant positive associations with the ScleroID score.


SSc is a complex disease, therefore it is difficult to characterize patients with low HRQoL, since the factors negatively affecting patients’ HRQoL are highly variable. Several tools are available to examine HRQoL in SSc patients [12, 13], yet only a few instruments are specific for SSc [14, 15, 45, 46]. Physicians predominantly focus on severe organ complications; however, these may not always be the main contributor to deteriorating HRQoL [1, 3, 8, 9, 19, 20]. The newly introduced ScleroID tool was developed with the help and contribution of SSc patients and covers the most important health dimensions which may affect HRQoL among SSc patients. First, we confirmed the associations identified by Becker and Dobrota et al. in our single-centre large SSc cohort. The Hungarian-validated version of ScleroID demonstrated a good performance. In our hands, the ScleroID tool showed a significant correlation with the Patient’s Global Assessment, yet not with Physician’s Global Assessment. This parallels previous observations which showed patients’ and physicians’ experiences regarding disease severity indeed differ [16, 49]. In the original ScleroID validation paper, Raynaud`s phenomenon, impaired hand function, pain and fatigue had the highest patient-reported disease impact evaluated by VAS [16]. In our single-centre study, we confirmed the importance of these particular findings (Table 3). Our single-centre study also confirmed good correlations identified by Becker and Dobrota et al. between widely used questionnaires (SF-36, HAQ-DI and sHAQ) and the ScleroID, allowing us to investigate further correlations [16] (Table 2). The lack of significant differences in ScleroID scores between dcSSc and lcSSc subsets may be partially explained by the high prevalence of musculoskeletal and GI involvements in both subsets and cardio-pulmonary manifestations also showed high prevalence in both subsets. Furthermore, dcSSc patients have a worse survival, and early severe cases are not enrolled to our cohort due to their early demise (in our previous paper, 19 out 106 deceased patients succumbed in the first 2 years to the disease) [4, 50, 51].

In our study, several functional and performance tests showed a moderate to good correlation regarding the ScleroID. These included the 6MWT reflecting overall cardiorespiratory function and GI-related complaints represented by MHISS and UCLA-GIT 2.0. Furthermore, both inflammatory joint symptoms and articular damage reflected by DAS28, CDAI, SDAI and qDASH scores and the overall hand disability tests correlated with the ScleroID. Muscular function measured by MMT8 is also well correlated with the ScleroID. Notably, a good correlation with overall disease activity was found. Additionally, important items including overall and articular pain and fatigue were also well represented in ScleroID. Conversely, the presence of internal organ involvements and digital ulcers, number of joint contractures and skin score did not substantially influence the ScleroID. Identification of the presence of a certain organ manifestation does not provide sufficient information in reference to its contribution to the decreased HRQoL of SSc patients.

Regarding the impaired hand function, we have shown both arthritis and irreversible joint damage are important contributors to the impaired ScleroID. Not surprisingly, significant correlations were identified with different measurements evaluating hand function. Hand function was implemented into the tool; it was the second most important parameter in the Delphi exercise indicating it distinctively impacts patients’ well-being [47]. Both activity scores (DAS28-CRP, DAS28-ESR, CDAI, SDAI) evaluating articular activity and performance test and quantitative measurements (HAMIS, HAI) assessing damage along with the number of contractures showed strong correlations with ScleroID score, though the latest not in lcSSc. It can be explained by the fact articular damage is more pronounced in dcSSc. Calculating the ScleroID score may help identifying patients with impaired hand function, especially in dcSSc. Joint tenderness, but not swelling, also showed a strong correlation in dcSSc. It is aligned with previous observations, in which tenderness, but not swelling, is more prevalent in SSc [52]. Seemingly, the new tool better represents articular pain than current inflammatory changes.

In addition to hand function, other important associations regarding the ScleroID score included the number of shortened digits, yet not the number of current DU. This may be explained due to the low prevalence of patients with current DU, which was less than in the cohort previously published by Becker et al. (13% vs. 7.5%). Presence of DU was also implemented in the tool [16].

Regarding internal organ involvements, ScleroID score showed a significant negative correlation with 6MWT. Decreased 6MWT may result from various causes including ILD, PAH cardiac or musculoskeletal involvement, and its decreased value is associated with a poor outcome [53]. From Sanges et al., the 6 MWT reflects more pulmonary vasculopathy than lung parenchymal involvement in SSc [54] and shows independent associations with the HAQ-DI. It is important to highlight, the ScleroID appropriately reflects the 6MWT. Seemingly, it is a valuable, simple and feasible instrument during follow-up among patients. The ScleroID score of patients affected with NYHA III-IV was also significantly impaired compared to the remainder of the cases. Regarding lung and heart involvement, the ScleroID was not sensitive enough for clinically mild symptoms; otherwise, it suitably reflected severe cardiorespiratory symptoms as patients with NYHAIII/IV state had significantly lower scores on ScleroID.

Significant associations were identified between the ScleroID tool and one of the most important contributors of decreased HRQoL, gastrointestinal involvement [19, 20] investigated by both objective and subjective tools. The newly introduced tool superbly reflects gastrointestinal involvement, especially its severe form, and the objectively proven oesophageal involvement (dysmotility or stricture on barium swallow test). Furthermore, the ScleroID showed correlations with two different self-assessment questionnaires investigating GI involvement, specifically, the MHISS and the UCLA-GIT 2.0 [14, 15, 46]. The new tool not only represented both major GI manifestations, oesophageal and bowel disease, but also correlated well with the symptoms regarding oral manifestations of the disease. Hence, the new tool may positively impact patients’ well-being along the entire GI tract.

The EUSTAR revised AI showed a good correlation with the ScleroID in all investigated subgroups [41,42,43]. The ScleroID may prove helpful in identifying patients with high disease activity along with other previously established factors. AI might be assessed in patients with long disease duration; however, the recently introduced composite response index in dcSSc due to the relatively low number of early dcSSc cases in this particular cross-sectional study was not assessed [55]. Previously some organ-specific questionnaires were developed to evaluate organ involvement in SSc patients [14, 29, 30, 46]. CHFS and qDASH showed associations with hand arthritis and flexion contractures, therefore, were able to detect patients with impaired hand function [22, 24, 26]. All SSc-specific questionnaires showed good correlations with the ScleroID and may prove beneficial to complement the use of the previously developed tools.

Our data suggest the ScleroID reflects both activity and damage associated with SSc. The items implemented to the tool covered the majority of different health dimensions playing a role in deteriorating HRQoL.

Other significant contributors regarding the decreased HRQoL [3] including fatigue and pain also showed significant strong correlations with the newly introduced tool, not surprisingly, since both items were implemented to the tool. This is aligned with the results of the Delphi exercise preceding the development of the tool: Patients ranked pain and fatigue as the fourth and fifth most important characteristic [16]. Fatigue is associated with many aspects of SSc, including GI symptoms, articular involvement and breathlessness [56], all showing strong correlations with the investigated tool, confirming its usefulness.

Our study bears several limitations. The ScleroID was designed as an overall measure of disease impact. The fact the score calculated in lcSSc and dcSSc showed no significant difference may be explained with no prior selection criteria established. Patients with both short and long-standing diseases were enrolled from both subsets, and patients with long disease duration may have developed coping mechanisms, while patients with early disease may have no severe complications. In our current cohort, disease duration was significantly longer in lcSSc patients when compared to dcSSc patients. Further analysis of data originating from different centres is essential to substantiate the real impact of the tool.


In conclusion, the validated Hungarian version of ScleroID performed well and all the basic findings described in the initial paper were effectively reproduced. The ScleroID reflects the GI manifestations of the disease, the deteriorated hand function, pain and fatigue, all surprisingly well. On the other hand, its performance in identifying patients with cardiopulmonary organ involvement was poor, since it is not sensitive enough to select patients with clinically mild involvement. However, the ScleroID well represented severe heart/pulmonary involvement measured by 6MWT and NYHA stage. The ScleroID covers many aspects of HRQoL, therefore, this particular newly developed instrument may help to identify patients with decreased HRQoL caused by both musculoskeletal and severe organ involvement.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to ethical issues but are available from the corresponding author on reasonable request.



Clinical Disease Activity Index


Cochin Hand Function Scale


Calculated right ventricular pressure


Disease Activity 28 Score C-Reactive Protein


Disease Activity Score 28 Erythrocyte Sedimentation Rate


Diffuse cutaneous SSc


Diffusing capacity of carbon monoxide


European Scleroderma Study Group Activity Index


Revised EUSTAR Activity Index


Forced vital capacity


Hand Anatomy Index


Hand Mobility in SSc scale


Health Assessment Questionnaire Disability Index


High-resolution computed tomography


Health-related quality of life


Interstitial pulmonary involvement


Limited cutaneous SSc


Mouth Handicap in Scleroderma Scale


Manual Muscle Test 8


Pulmonary arterial hypertension


Patient-reported outcome measure


Quick Questionnaire of the Disability of the Hands and the Arms and Shoulders


Random Forest


Right heart catheterization


EULAR SSc Impact of Disease


Simplified Disease Activity Index


Short-Form Health-Survey 36

SF-36 MCS:

SF-36 Mental Component Score

SF.36 PCS:

SF-36 Physical Component Score


Scleroderma HAQ


Systemic sclerosis


University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0


Visual analogue scales


Six-minute walking test


  1. Clements PJWW, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum. 1999;42(11):2372–80.

    Article  CAS  PubMed  Google Scholar 

  2. Rannou FPS, Berezné A, Baubet T, Le-Guern V, Cabane J, Guillevin L, Revel M, Fermanian J, Mouthon L. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum. 2007;57(1):94–102.

    Article  PubMed  Google Scholar 

  3. Frantz CAJ, Distler O, Amrouche F, Godard D, Kennedy AT, Connolly K, Varga J, Matucci-Cerinic M, Allanore Y. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum. 2016;46(1):115–23.

    Article  PubMed  Google Scholar 

  4. Nagy G, Minier T, Varju C, Faludi R, Kovacs KT, Lorand V, et al. The presence of small joint contractures is a risk factor for survival in 439 patients with systemic sclerosis. Clin Exp Rheumatol. 2017;35 Suppl 106(4):61–70.

    PubMed  Google Scholar 

  5. Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67(1):59–63.

    Article  CAS  PubMed  Google Scholar 

  6. Khanna D FD, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR, Relaxin Study Group; Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the health assessment questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol. 2005;32(5):832–40.

  7. Allanore Y, Bozzi S, Terlinden A, Huscher D, Amand C, Soubrane C, et al. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Res Ther. 2020;22(1):257.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Danieli EAP, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, Franceschini F, Cattaneo R. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol. 2005;24(1):48–54.

    Article  PubMed  Google Scholar 

  9. Jaeger VK, Distler O, Maurer B, Czirjak L, Lorand V, Valentini G, et al. Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology (Oxford). 2018;57(3):441–50.

    Article  PubMed  Google Scholar 

  10. Johnson SRGD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol. 2006;33(6):1117–22.

    PubMed  Google Scholar 

  11. Pope J. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler’s Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud’s Condition Score (RCS). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S98-111.

    Article  PubMed  Google Scholar 

  12. Ware JE Jr, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  13. Fries JFSP, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789–93.

    CAS  PubMed  Google Scholar 

  14. Khanna DHR, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Fathi N, Bechtel A, Furst DE. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61(9):1257–63.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Tuba ÉVC, Szigeti N, Farkas N, Sütő G, Czirják L. A UCLA scleroderma gastrointestinális kérdőív 2.0 magyar nyelvű validálása. Magyar Reumatol. 2014;55:85–90.

    Google Scholar 

  16. Becker MO, Dobrota R, Garaiman A, Debelak R, Fligelstone K, Tyrrell Kennedy A, et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Ann Rheum Dis. 2022;81(4):507–15.

    Article  PubMed  Google Scholar 

  17. Nagy GKG, Varjú C, Minier T, Czirják L. EULAR Systemic sclerosis Impact of Disease (ScleroID) kérdőív adaptálása és validálása magyar nyelvre. Immunol Szemle. 2022;14(1):4–10.

    Google Scholar 

  18. Khanna D, Allanore Y, Denton CP, Matucci-Cerinic M, Pope J, Hinzmann B, et al. Patient perception of disease burden in diffuse cutaneous systemic sclerosis. J Scleroderma Relat Disord. 2020;5(1):66–76.

    Article  PubMed  Google Scholar 

  19. Bassel MHM, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford). 2011;50(4):762–7.

    Article  PubMed  Google Scholar 

  20. Suarez-Almazor MEKM, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol. 2007;34(8):1718–26.

    PubMed  Google Scholar 

  21. Varjú C, Péntek M, Lóránd V, Nagy G, Minier T, Czirják L. Musculoskeletal involvement in systemic scelrosis: an unexplored aspect of the disease. J Scleroderma Relat Disord. 2017;1:19–32.

    Article  Google Scholar 

  22. Balint Z, Farkas H, Farkas N, Minier T, Kumanovics G, Horvath K, et al. A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-68-74.

    Google Scholar 

  23. Mouthon L, Mestre-Stanislas C, Berezne A, Rannou F, Guilpain P, Revel M, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis. 2010;69(1):214–7.

    Article  CAS  PubMed  Google Scholar 

  24. Lorand V, Balint Z, Komjati D, Nemeth B, Minier T, Kumanovics G, et al. Validation of disease activity indices using the 28 joint counts in systemic sclerosis. Rheumatology (Oxford). 2016;55(10):1849–58.

    Article  PubMed  Google Scholar 

  25. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum. 2001;44(3):653–61.

    Article  CAS  PubMed  Google Scholar 

  26. Lorand V, Nagy G, Balint Z, Komjati D, Minier T, Kumanovics G, et al. Sensitivity to change of joint count composite indices in 72 patients with systemic sclerosis. Clin Exp Rheumatol. 2021;39 Suppl 131(4):77–84.

    Article  PubMed  Google Scholar 

  27. Roberts-Thomson AJ, Massy-Westropp N, Smith MD, Ahern MJ, Highton J, Roberts-Thomson PJ. The use of the hand anatomic index to assess deformity and impaired function in systemic sclerosis. Rheumatol Int. 2006;26(5):439–44.

    Article  CAS  PubMed  Google Scholar 

  28. Sandqvist G, Nilsson JA, Wuttge DM, Hesselstrand R. Development of a modified hand mobility in scleroderma (HAMIS) test and its potential as an outcome measure in systemic sclerosis. J Rheumatol. 2014;41(11):2186–92.

    Article  PubMed  Google Scholar 

  29. Varjú CGK, Farkas N, Kárpáti E, Lóránd V, Czirják L. A Cochin kézfunkciót felmérő teszt Magyarországra történő adaptálása és validálása szisztémás sclerosisos, valamint rheumatoid arthritises betegeknél. Magyar Reumatol. 2013;54(2):82–9.

    Google Scholar 

  30. Varju C, Balint Z, Solyom AI, Farkas H, Karpati E, Berta B, et al. Cross-cultural adaptation of the disabilities of the arm, shoulder, and hand (DASH) questionnaire into Hungarian and investigation of its validity in patients with systemic sclerosis. Clin Exp Rheumatol. 2008;26(5):776–83.

    CAS  PubMed  Google Scholar 

  31. Brower LM, Poole JL. Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum. 2004;51(5):805–9.

    Article  PubMed  Google Scholar 

  32. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol. 2017;35 Suppl 106(4):75–81.

    PubMed  Google Scholar 

  34. Adler S, Huscher D, Siegert E, Allanore Y, Czirjak L, DelGaldo F, et al. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20(1):17.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Komocsi A, Pinter T, Faludi R, Magyari B, Bozo J, Kumanovics G, et al. Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis. 2010;69(1):202–5.

    Article  CAS  PubMed  Google Scholar 

  36. Faludi R, Kolto G, Bartos B, Csima G, Czirjak L, Komocsi A. Five-year follow-up of left ventricular diastolic function in systemic sclerosis patients: determinants of mortality and disease progression. Semin Arthritis Rheum. 2014;44(2):220–7.

    Article  PubMed  Google Scholar 

  37. Ross L, Prior D, Proudman S, Vacca A, Baron M, Nikpour M. Defining primary systemic sclerosis heart involvement: a scoping literature review. Semin Arthritis Rheum. 2019;48(5):874–87.

    Article  PubMed  Google Scholar 

  38. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.

    Article  Google Scholar 

  39. Nogradi A, Porpaczy A, Porcsa L, Minier T, Czirjak L, Komocsi A, et al. Relation of right atrial mechanics to functional capacity in patients with systemic sclerosis. Am J Cardiol. 2018;122(7):1249–54.

    Article  PubMed  Google Scholar 

  40. Denton CP, Lapadula G, Mouthon L, Muller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48 Suppl 3:iii32-5.

    CAS  PubMed  Google Scholar 

  41. Valentini G, Bencivelli W, Bombardieri S, D’Angelo S, Della Rossa A, Silman AJ, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis. 2003;62(9):901–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76(1):270–6.

    Article  CAS  PubMed  Google Scholar 

  43. Minier T, Nagy Z, Balint Z, Farkas H, Radics J, Kumanovics G, et al. Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford). 2010;49(6):1133–45.

    Article  PubMed  Google Scholar 

  44. Nagy Z, Balint Z, Farkas H, Radics J, Kumanovics G, Minier T, et al. Establishment and partial validation of a patient skin self-assessment questionnaire in systemic sclerosis. Rheumatology (Oxford). 2009;48(3):309–14.

    Article  PubMed  Google Scholar 

  45. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40(11):1984–91.

    Article  CAS  PubMed  Google Scholar 

  46. Mouthon L, Rannou F, Berezne A, Pagnoux C, Arene JP, Fois E, et al. Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis. 2007;66(12):1651–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100–8.

    CAS  PubMed  Google Scholar 

  48. van der Stap DK, Rider LG, Alexanderson H, Huber AM, Gualano B, Gordon P, et al. Proposal for a candidate core set of fitness and strength tests for patients with childhood or adult idiopathic inflammatory myopathies. J Rheumatol. 2016;43(1):169–76.

    Article  PubMed  Google Scholar 

  49. Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350:g7818.

    Article  PubMed  Google Scholar 

  50. Kuwana M, Allanore Y, Denton CP, Distler JHW, Steen V, Khanna D, et al. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and modified rodnan skin thickness score. Arthritis Rheumatol. 2022;74(3):518–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Volkmann ER, McMahan Z. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment. Curr Opin Rheumatol. 2022;34(6):328–36.

    Article  PubMed  Google Scholar 

  52. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010;37(7):1488–501.

    Article  PubMed  Google Scholar 

  53. Vandecasteele E, De Pauw M, De Keyser F, Decuman S, Deschepper E, Piette Y, et al. Six-minute walk test in systemic sclerosis: a systematic review and meta-analysis. Int J Cardiol. 2016;212:265–73.

    Article  PubMed  Google Scholar 

  54. Sanges S, Giovannelli J, Sobanski V, Morell-Dubois S, Maillard H, Lambert M, et al. Factors associated with the 6-minute walk distance in patients with systemic sclerosis. Arthritis Res Ther. 2017;19(1):279.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Khanna D, Huang S, Lin CJF, Spino C. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Ann Rheum Dis. 2021;80(5):641–50.

    Article  PubMed  Google Scholar 

  56. Carandang K, Poole J, Connolly D. Fatigue and activity management education for individuals with systemic sclerosis: adaptation and feasibility study of an intervention for a rare disease. Musculoskeletal Care. 2022;20(3):593–604.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


Open access funding provided by University of Pécs. This work was supported by’PEPSYS GINOP-2.3.2–15-2016–00050—Stratégiai K + F műhelyek kiválósága: A peptiderg szignalizáció komplexitása és szerepe szisztémás betegségekben’ grant and TKP-2021-EGA-10 has been implemented with the support provided from the National Research, Development and Innovation Fund of Hungary, financed under the TKP-2021-EGA funding scheme.

Author information

Authors and Affiliations



GN had a substantial contributions to the conception, the acquisition, analysis, interpretation of data; RD interpretation of data; MB interpretation of data; TM the acquisition, analysis, CV the acquisition, analysis, GK interpretation of data; OD interpretation of data, LC interpretation of data; and design of the work. GN, RD, MB, CV, TM, GK, OD, LC to have approved the submitted version (and any substantially modified version that involves the author's contribution to the study); and GN, RD, MB, CV, TM, GK, OD, LC to have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Corresponding author

Correspondence to László Czirják.

Ethics declarations

Ethics approval and consent to participate

All patients submitted their informed written consent to the study, which was conducted in full accordance with the Declaration of Helsinki and was approved by the National Research Ethics Committee (30636–3/2017/EKU).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagy, G., Dobrota, R., Becker, M.O. et al. Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis. Arthritis Res Ther 25, 84 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: